249 related articles for article (PubMed ID: 15369177)
1. Primary resected meningiomas: relapses and proliferation markers.
Kalala JP; Caemaert J; De Ridder L
In Vivo; 2004; 18(4):411-6. PubMed ID: 15369177
[TBL] [Abstract][Full Text] [Related]
2. PCNA, Ki-67 and hTERT in residual benign meningiomas.
Maes L; Kalala JP; Cornelissen M; De Ridder L
In Vivo; 2006; 20(2):271-5. PubMed ID: 16634530
[TBL] [Abstract][Full Text] [Related]
3. Can recurrence of meningiomas be predicted?
Kalala JP; Benoit D; De Ridder L
Anticancer Res; 2004; 24(4):2319-24. PubMed ID: 15330178
[TBL] [Abstract][Full Text] [Related]
4. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
5. Proliferation and progesterone receptor status in benign meningiomas are not age dependent.
Roser F; Nakamura M; Ritz R; Bellinzona M; Dietz K; Samii M; Tatagiba MS
Cancer; 2005 Aug; 104(3):598-601. PubMed ID: 15952201
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
7. S100A5: a marker of recurrence in WHO grade I meningiomas.
Hancq S; Salmon I; Brotchi J; De Witte O; Gabius HJ; Heizmann CW; Kiss R; Decaestecker C
Neuropathol Appl Neurobiol; 2004 Apr; 30(2):178-87. PubMed ID: 15043715
[TBL] [Abstract][Full Text] [Related]
8. Factors predicting local tumor control after gamma knife stereotactic radiosurgery for benign intracranial meningiomas.
DiBiase SJ; Kwok Y; Yovino S; Arena C; Naqvi S; Temple R; Regine WF; Amin P; Guo C; Chin LS
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1515-9. PubMed ID: 15590183
[TBL] [Abstract][Full Text] [Related]
9. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
11. Clinical features and immunohistochemical expression levels of androgen, estrogen, progesterone and Ki-67 receptors in relationship with gross-total resected meningiomas relapse.
Tao Y; Liang G; Li Z; Wang Y; Wu A; Wang H; Lu Y; Liu Z; Hu G
Br J Neurosurg; 2012 Oct; 26(5):700-4. PubMed ID: 22616825
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
[TBL] [Abstract][Full Text] [Related]
13. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
Abdelzaher E; El-Gendi SM; Yehya A; Gowil AG
Br J Neurosurg; 2011 Dec; 25(6):707-13. PubMed ID: 20979437
[TBL] [Abstract][Full Text] [Related]
14. [Proliferative markers of meningiomas: immunohistochemical analysis and prognostic value].
Korshunov AG; Shishkina LV; Golanov AV
Arkh Patol; 2002; 64(1):29-33. PubMed ID: 11889696
[TBL] [Abstract][Full Text] [Related]
15. [Importance of meningioma. Clinico-epidemiologic and histologic studies].
Guski M; Martin H
Zentralbl Neurochir; 1984; 45(3):219-32. PubMed ID: 6506933
[TBL] [Abstract][Full Text] [Related]
16. Correlation of apparent diffusion coefficient with Ki-67 proliferation index in grading meningioma.
Tang Y; Dundamadappa SK; Thangasamy S; Flood T; Moser R; Smith T; Cauley K; Takhtani D
AJR Am J Roentgenol; 2014 Jun; 202(6):1303-8. PubMed ID: 24848829
[TBL] [Abstract][Full Text] [Related]
17. Expression of apoptotic and proliferation markers in meningiomas.
Konstantinidou AE; Pavlopoulos PM; Patsouris E; Kaklamanis L; Davaris P
J Pathol; 1998 Nov; 186(3):325-30. PubMed ID: 10211124
[TBL] [Abstract][Full Text] [Related]
18. Expression of the proliferating cell nuclear antigen and clinicopathological features in intracranial meningiomas.
Kim CH; Cheong JH; Bak KH; Kim JM; Oh SJ
J Clin Neurosci; 2001 May; 8 Suppl 1():44-8. PubMed ID: 11386825
[TBL] [Abstract][Full Text] [Related]
19. The hTERT protein as a marker for malignancy in meningiomas.
Kalala JP; Maes L; Vandenbroecke C; de Ridder L
Oncol Rep; 2005 Feb; 13(2):273-7. PubMed ID: 15643510
[TBL] [Abstract][Full Text] [Related]
20. Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone.
Maillo A; Orfao A; Espinosa AB; Sayagués JM; Merino M; Sousa P; Lara M; Tabernero MD
Neuro Oncol; 2007 Oct; 9(4):438-46. PubMed ID: 17704362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
